A Perspective on Longevity Biotech Investment from James Peyer of Kronos BioVentures

James Peyer, formerly of Apollo Ventures and now at the larger Kronos BioVentures, has a range of interesting views on the new and growing longevity biotechnology industry. Apollo Ventures was one of the earlier longevity-focused funds to emerge from the comparatively small community of scientists, patient advocates, and investors enthusiastic to accelerate progress towards the treatment of aging as a medical condition. The presentation here was given earlier this year at the Ending Age-Related Diseases conference organized by the Life Extension Advocacy Foundation. In the matter of creating new medical therapies, there is a huge, well known, gaping chasm between academia and industry. Neither side of the chasm is all that good at the process of transferring promising projects from proof of principle in the

From http://besthealthnews.com/2019/10/a-perspective-on-longevity-biotech-investment-from-james-peyer-of-kronos-bioventures/?utm_source=rss&utm_medium=rss&utm_campaign=a-perspective-on-longevity-biotech-investment-from-james-peyer-of-kronos-bioventures

from
https://healthnews010.wordpress.com/2019/10/31/a-perspective-on-longevity-biotech-investment-from-james-peyer-of-kronos-bioventures/

from https://jamesjohnson10.blogspot.com/2019/10/a-perspective-on-longevity-biotech.html

from
https://jamesjohnson101.tumblr.com/post/188715465658